DE1593782B2 - 1-NITRILOPHENOXY- 2- HYDROXY -3- TERT.BUTYLAMINOPROPANE, THE PROCESS FOR THEIR MANUFACTURING AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE - Google Patents
1-NITRILOPHENOXY- 2- HYDROXY -3- TERT.BUTYLAMINOPROPANE, THE PROCESS FOR THEIR MANUFACTURING AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THESEInfo
- Publication number
- DE1593782B2 DE1593782B2 DE1967B0093025 DEB0093025A DE1593782B2 DE 1593782 B2 DE1593782 B2 DE 1593782B2 DE 1967B0093025 DE1967B0093025 DE 1967B0093025 DE B0093025 A DEB0093025 A DE B0093025A DE 1593782 B2 DE1593782 B2 DE 1593782B2
- Authority
- DE
- Germany
- Prior art keywords
- formula
- tert
- choh
- compounds
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Description
Houben —Weyl, Methoden der organ. Chemie, 1. und 2. Auflage.Houben-Weyl, Methods of the organ. Chemistry, 1st and 2nd edition.
Die Verbindungen der allgemeinen Formel I besitzen an der — CHOH-Gruppierung ein asymmetrisches C-Atom und kommen daher in Form von Racematen wie auch von optisch aktiven Antipoden vor. Die optisch aktiven Verbindungen können erhalten werden, indem man die erhaltenen Racemate auf übliche Weise, beispielsweise mit Dibenzoylweinsäure oder Bromcamphersulfonsäure, in ihre optischen Antipoden spaltet.The compounds of the general formula I have an asymmetric group on the - CHOH group C atom and therefore occur in the form of racemates as well as optically active antipodes. the optically active compounds can be obtained by converting the racemates obtained in a conventional manner, for example with dibenzoyltartaric acid or bromocamphorsulfonic acid, splits into their optical antipodes.
Die nach den Verfahren a) bis h) erhaltenen Verbindungen der allgemeinen Formel 1 können gewünschtenfalls in üblicher Weise in ihre physiologisch verträglichen Säureadditionssalze überführt werden. Für die Salzbildung geeignete Säuren sind beispielsweise Salz-, Bromwasserstoff-, Schwefel-, Methansulfon-, Malein-, Essig-, Oxal-, Milch- und Weinsäure.The compounds of general formula 1 obtained by processes a) to h) can, if desired be converted in the usual way into their physiologically acceptable acid addition salts. Acids suitable for salt formation are, for example, hydrochloric, hydrogen bromide, sulfur, methanesulfone, Maleic, acetic, oxalic, lactic and tartaric acids.
Die Verbindungen der allgemeinen Formel 1 bzw. deren physiologisch verträgliche Säureadditionssalze haben wertvolle therapeutische, insbesondere j3-adrenolytische Eigenschaften und können daher beispielsweise zur Behandlung oder Prophylaxe von Erkrankungen der Herzkranzgefäße und zur Behandlung von Herzarrhythmien, insbesondere von Tachycardien, an Menschen eingesetzt werden. Auch die blutdrucksenkenden Eigenschaften der Verbindung sind therapeutisch wertvoll.The compounds of general formula 1 or their physiologically acceptable acid addition salts have valuable therapeutic, in particular j3-adrenolytic properties and can therefore, for example for the treatment or prophylaxis of diseases of the coronary arteries and for the treatment of cardiac arrhythmias, in particular by tachycardia, are used on humans. Even the antihypertensive ones Properties of the compound are therapeutically valuable.
Als besonders wertvoll hat sich dabei das 1 -(2-Nitrilophenoxy)-2-hydroxy-3-tert.-butylaminopropan herausgestellt. Als Einzeldosis der erfindungsgemäßen Verbindüngen sind 1 —300 mg (0.016 — 5 mg/kg), vorzugsweise 15-100 mg (0,25-1,66 mg/kg) für die orale und 0,1-25 mg (0,002-0,4 mg/kg) für die parenteral Anwendung am Menschen geeignet.1 - (2-Nitrilophenoxy) -2-hydroxy-3-tert.-butylaminopropane has proven to be particularly valuable exposed. As a single dose of the compounds according to the invention are 1-300 mg (0.016-5 mg / kg), preferably 15-100 mg (0.25-1.66 mg / kg) for the oral and 0.1-25 mg (0.002-0.4 mg / kg) for the parenteral Suitable for use on humans.
Die therapeutische Wirkung der erfindungsgemäßen Verbindung ergibt sich aus folgenden biologischen Versuchen:The therapeutic effect of the compound according to the invention results from the following biological Try:
Verbindunglink
Iso-Iso-
proterenol-proterenol
antagon.antagon.
Wirkungeffect
1-(2-Nitrilophenoxy)-2-hydroxy-3-tert.-Butylaminopropan · HCI1- (2-Nitrilophenoxy) -2-hydroxy-3-tert-butylaminopropane · HCl
a) 15 g (0,085MoI) l-(2-Nitrilophenoxy)-2,3-epoxypropan werden in 100 ml Äthanol gelöst und 18,6 g (0,255 Mol) tert.-Butylamin zugegeben. Nach einstündigem Stehen bei Raumtemperatur wird zwei Stunden auf 60 bis 70°C erwärmt; anschließend werden die flüchtigen Anteile i. Vak. abdestilliert. Der verbleibende Rückstand wird mit verdünnter HCl digeriert; die unlöslichen Anteile werden abgesaugt. Das Filtrat wird sodann mit NaOH alkalisch gestellt und die ausfallende Base in Äther aufgenommen. Nach Trocknen der Ätherlösung über MgSC>4 wird der Äther abdestilliert und der verbleibende Rückstand in Äthanol gelöst. Durch Zugabe von ätherischer HCl wird das Hydrochlorid kristallin ausgefällt, das nach Umkristallisation aus Äthanol unter Zusatz von Äther rein erhalten wird. Ausbeute: 9,8 g, Fp. 163- 165°C.a) 15 g (0.085 mol) 1- (2-nitrilophenoxy) -2,3-epoxypropane are dissolved in 100 ml of ethanol and 18.6 g (0.255 mol) of tert-butylamine are added. After an hour Standing at room temperature is heated to 60 to 70 ° C for two hours; then the volatile components i. Vac. distilled off. The remaining residue is digested with dilute HCl; the insoluble parts are sucked off. The filtrate is then made alkaline with NaOH and the precipitated Base taken up in ether. After drying the ethereal solution over MgSC> 4, the ether is distilled off and the remaining residue dissolved in ethanol. By adding essential HCl the hydrochloride becomes precipitated in crystalline form, which is obtained in pure form after recrystallization from ethanol with the addition of ether. Yield: 9.8 g, m.p. 163-165 ° C.
Berechnet: C 59,05, H 7,73, N 9,84;
gefunden: C 59,01, H 7,21, N 9,88.Calculated: C 59.05, H 7.73, N 9.84;
Found: C 59.01, H 7.21, N 9.88.
b) 2,56 g (0,01 Mol) l-(2-Nitrilophenoxy)-2-hydroxy-3-brompropan werden in 20 ml Tetralin mit 3,44 g (0,02 Mol) N,N'-Di-tert.-butylharnstoff zwei Stunden auf 200" C erhitzt. Nach dem Abkühlen werden 20 ml Äther zugegeben und die organische Phase mit verdünnter HCl ausgeschüttelt. Nach Abtrennung der wäßrigen Phase wird diese mit NaOH alkalisch gestellt. Die ausfallenden basischen Anteile werden in Äther aufgenommen, die Ätherlösung abgetrennt und über MgSÜ4 getrocknet. Der Äther wird abdestilliert, der Rückstand (1,5 g) in wenig Äther gelöst und filtriert. Dem Filtrat wird ätherische HCI zugesetzt, wobei das Hydrochlorid ausfällt. Es wird abgesaugt und zweimal aus wenig Äthanol umkristallisiert. Ausbeute: 0,4 g, Fp. 159-163°C.b) 2.56 g (0.01 mol) of 1- (2-nitrilophenoxy) -2-hydroxy-3-bromopropane are dissolved in 20 ml of tetralin with 3.44 g (0.02 mol) N, N'-di-tert-butylurea heated to 200 ° C. for two hours. After cooling, 20 ml of ether are added added and the organic phase extracted with dilute HCl. After separation of the aqueous Phase this is made alkaline with NaOH. The precipitating basic parts become ether taken up, the ether solution separated and dried over MgSÜ4. The ether is distilled off, the The residue (1.5 g) was dissolved in a little ether and filtered. Ethereal HCI is added to the filtrate, the Hydrochloride precipitates. It is filtered off with suction and recrystallized twice from a little ethanol. Yield: 0.4 g, m.p. 159-163 ° C.
Berechnet: C 59,05, H 7,43, N 9,84;
gefunden: C 59,10, H 7,36, N 9,78.Calculated: C 59.05, H 7.43, N 9.84;
Found: C 59.10, H 7.36, N 9.78.
A. Gemäß Stand der Technik
(BE-PS 6 41 133 und 6 52 336)
l-m-Tolyloxy-Z-hydroxy-S-iso- Stach DCi*)
propylaminopropan · HQ =A. According to the state of the art
(BE-PS 6 41 133 and 6 52 336)
lm-Tolyloxy-Z-hydroxy-S-iso-Stach DCi *) propylaminopropane · HQ =
Doberol® (Warenzeichen der
Anmelderin)Doberol® (trademark of
Applicant)
B. ErfindungsgetnäßB. Invention item
l-(2-Nitrilophenoxy)-2-hydroxy- 165fach1- (2-nitrilophenoxy) -2-hydroxy-165 fold
3-tert-butyiaminopropun ■ HCl DCI3-tert-butyiaminopropune ■ HCl DCI
1 -(2-Nitrilophenoxy)-2-hydroxy- 161,5f ach1 - (2-nitrilophenoxy) -2-hydroxy-161.5 ach
3-tert.-butylaminopropan-oxalat DCI3-tert-butylaminopropane oxalate DCI
(—)-1 -(2-Nitrilophenoxy)-2-hydroxy- 273f ach(-) - 1 - (2-Nitrilophenoxy) -2-hydroxy-273f ach
3-tert.-butylaminopropan · HCl DCI3-tert-butylaminopropane · HCl DCI
*) Die Tests wurden am lebenden Meerschweinchen durchgeführt. Als Standardsubstanz diente das 3,4-Dichlorisoproterenol (= DCl), dessen Wirkung = 1 gesetzt wurde.*) The tests were carried out on live guinea pigs. The 3,4-dichloroisoproterenol served as the standard substance (= DCl), whose effect = 1 was set.
Die galenische Verarbeitung der Verbindungen der Formel 1 zu den üblichen Anwendungsformen wie Lösungen, Emulsionen, Tabletten, Dragees oder Depotformen kann in bekannter Weise unter Heranziehung der dafür gebräuchlichen galenischen Hilfsstoffe erfolgen. The pharmaceutical processing of the compounds of formula 1 to the usual application forms such as Solutions, emulsions, tablets, coated tablets or depot forms can be used in a known manner the pharmaceutical auxiliaries commonly used for this purpose.
Die folgenden Beispiele erläutern die Erfindung:The following examples illustrate the invention:
c) 1,66 g (0,005 Mol) 1-(2-Nitrilophenoxy)-3-tert.-butylamino-propanol-2-tetrahydropyranyläther-Oxalat werden in 5 ml verdünnter HCl 2 Stunden im kochenden Wasserbad erhitzt. Nach Abkühlung wird mit NaOH alkalisch gestellt und die ausfallende Base in Äther aufgenommen. Die ätherische Lösung wird über MgSO4 getrocknet, anschließend wird der Äther i. Vak. verdampft. Der Rückstand wird wie üblich aufgearbeitet, wobei sich das Hydrochlorid im Schmelzpunkt, Mischschmelzpunkt und Rf-Wert im Dünnschichtchromatogramm als identisch mit der unter a) und b) beschriebenen Verbindung erweist.c) 1.66 g (0.005 mol) of 1- (2-nitrilophenoxy) -3-tert-butylamino-propanol-2-tetrahydropyranyl ether oxalate are heated in 5 ml of dilute HCl for 2 hours in a boiling water bath. After cooling, it is washed with NaOH made alkaline and taken up the precipitating base in ether. The essential solution is over MgSO4 dried, then the ether i. Vac. evaporates. The residue is worked up as usual, where the hydrochloride is in the melting point, mixed melting point and Rf value in the thin layer chromatogram proves to be identical to the compound described under a) and b).
Berechnet: C 59,05, H 7,43, N 9,84;
gefunden: C 58,95, H 7,44, N 9,69.Calculated: C 59.05, H 7.43, N 9.84;
Found: C 58.95, H 7.44, N 9.69.
Der als Ausgangsmaterial benutzte Tetrahydropyranyläther wird wie folgt hergestellt:The tetrahydropyranyl ether used as the starting material is prepared as follows:
7,8 g (0,05 Mol) 1-(2-Nitrilophenoxy)-2-hydroxy-3-brompropan werden mit 16,8 g (0,2 Mol) Dihydropyran und einer Spatelspitze p-Toluolsulfosäure verrührt, wobei eine leicht exotherme Reaktion einsetzt. Nachdem diese bei 35°C abgeklungen ist, wird 30 Minuten auf 50 —60cC erwärmt. Dann wird in 100 ml Benzol gelöst und 15 ml tert.-Butylamin zugegeben. Der Ansatz wird nach zweitägigem Stehen bei Raumtempe-,' ralur 6 Stunden unter Rückfluß gekocht, sodann im7.8 g (0.05 mol) of 1- (2-nitrilophenoxy) -2-hydroxy-3-bromopropane are stirred with 16.8 g (0.2 mol) of dihydropyran and a spatula tip of p-toluenesulfonic acid, with a slightly exothermic Reaction sets in. After this has decayed at 35 ° C, 30 minutes at 50 -60 c C is heated. It is then dissolved in 100 ml of benzene and 15 ml of tert-butylamine are added. After standing for two days at room temperature, the batch is refluxed for 6 hours, then im
Vakuum eingeengt. Der Rückstand wird in Äther gelöst und mit Wasser ausgeschüttelt. Die organische Phase wird über MgSO4 getrocknet, der Äther abdestilliert und der Rückstand (11,9 g) in wenig Äther gelöst. Diese Lösung wird mit einer ätherischen Oxalsäurelösung vereinigt, wobei das Oxalat auskristallisiert. Es wird abgetrennt und aus Acetonitril umkristallisiert. Fp. 102-105°C(Zers.).Reduced vacuum. The residue is dissolved in ether and extracted with water. The organic phase is dried over MgSO 4 , the ether is distilled off and the residue (11.9 g) is dissolved in a little ether. This solution is combined with an essential oxalic acid solution, the oxalate crystallizing out. It is separated off and recrystallized from acetonitrile. M.p. 102-105 ° C (dec.).
d) 2 g l-(2-Nitrilophenoxy)-2-hydroxy-3-(N-acetyI-N-tert.-butylamino)-propan werden in 20 ml Äthanol mit 4 g KOH in 6 ml H2O versetzt, unter Rühren zwei Stunden unter Rückfluß zum Sieden erhitzt und der Alkohol dann i. Vak. abdestilliert. Der Rückstand wird mit verdünnter HCI angesäuert, zweimal ausgeäthert, die wäßrige Phase mit NaOH alkalisch gestellt und die ausfallende Base in Äther aufgenommen. Die ätherische Lösung wird über MgSO4 getrocknet und der Äther abdestilliert. Als Rückstand verbleiben 650 mg Rohbase, die in wenig Äthanol gelöst wird. Nach Zugabe von ätherischer HCI fallen farblose Kristalle aus, die nochmals aus Äthanol/Äther umkristallisiert werden. Fp. 160-163° C.d) 2 g of l- (2-nitrilophenoxy) -2-hydroxy-3- (N-acetyI-N-tert-butylamino) propane are mixed with 4 g of KOH in 6 ml of H 2 O in 20 ml of ethanol, under Stirring heated to boiling under reflux for two hours and the alcohol then i. Vac. distilled off. The residue is acidified with dilute HCl and extracted twice with ether, the aqueous phase is made alkaline with NaOH and the base which precipitates is taken up in ether. The ethereal solution is dried over MgSO 4 and the ether is distilled off. 650 mg of crude base remain as residue, which is dissolved in a little ethanol. After the addition of ethereal HCI, colorless crystals precipitate, which are recrystallized again from ethanol / ether. Mp. 160-163 ° C.
Berechnet: C 59;05, H 7,43, N 9,84;
gefunden: C 59,25, H 7,66, N 9,77.Calculated: C 59.05, H 7.43, N 9.84;
Found: C 59.25, H 7.66, N 9.77.
e) 3,5 g (0.011 Mol) N,N'-Di-tert.-butyl-N-[(2-hydroxy-3-o-nitrilophenoxy)-propyl]-harnstoff werden in 10 ml Tetralin unter Zugabe einer Spaltelspitze LiCi zwei Stunden auf 2000C erhitzt. Die abgekühlte Lösung wird sodann mit verdünnter HCl ausgeschüttelt. Die wäßrige Phase wird nach Abtrennung mit NaOH alkalisch gestellt und die sich abscheidende Base in Äther aufgenommen. Die Ätherlösung wird abgesaugt, über MgSO4 getrocknet und i. Vak. eingeengt. Der Rückstand (2,2 g) wird in wenig Äthanol gelöst, ätherische HCI zugegeben und das ausfallende Hydrochlorid abgesaugt. Nach nochmaligem Umfallen aus Äthanol unter Zugabe von Äther Fp. 157— 1610C.e) 3.5 g (0.011 mol) of N, N'-di-tert-butyl-N - [(2-hydroxy-3-o-nitrilophenoxy) propyl] urea are dissolved in 10 ml of tetralin with the addition of a splitting tip LiCl heated two hours 200 0 C. The cooled solution is then extracted by shaking with dilute HCl. After separation, the aqueous phase is made alkaline with NaOH and the base which separates out is taken up in ether. The ether solution is filtered off with suction, dried over MgSO 4 and i. Vac. constricted. The residue (2.2 g) is dissolved in a little ethanol, ethereal HCI is added and the precipitated hydrochloride is filtered off with suction. After repeated reprecipitation from ethanol with the addition of ether, mp. 157- 161 0 C.
Berechnet: C 59,05, H 7,43, N 9,84;
gefunden: C 58,95, H 7,56, N 9,81.Calculated: C 59.05, H 7.43, N 9.84;
Found: C 58.95, H 7.56, N 9.81.
1 -(4-NitriIophenoxy)-2-hydroxy-3-tert.-Butylaminopropan ■ HCI1 - (4-NitriIophenoxy) -2-hydroxy-3-tert-butylaminopropane ■ HCI
a) 5,7 g (0,02 Mol) 3-tert.-Butyl-5-(4-nitrilo-phenoxymethyl)-oxazolidinon-(2) werden in 50 ml Äthanol gelöst. Nach Zugabe einer Lösung von 10 g KOH in 15 ml Wasser wird zwei Stunden unter Rückfluß gekocht. Das Äthanol wird i. Vak. abdestiliiert und der Rückstand mit Äther ausgeschüttelt. Die ätherische Phase wird abgetrennt, über MgSO4 getrocknet und filtriert. Nach Einengen der Ätherlösung wird die feste, rohe Base aus Essigester umkristallisiert. Fp. 100-1050C. Nach Lösen der kristallinen Base in Äthanol wird ätherische Salzsäure zugegeben, das Hydrochlorid isoliert und nochmals aus Äthanol/Äther umkristallisiert. Fp. 187- 1890C, Ausbeute: 1,9 g.a) 5.7 g (0.02 mol) of 3-tert-butyl-5- (4-nitrilo-phenoxymethyl) -oxazolidinone- (2) are dissolved in 50 ml of ethanol. After adding a solution of 10 g of KOH in 15 ml of water, the mixture is refluxed for two hours. The ethanol is i. Vac. distilled off and the residue extracted with ether. The ethereal phase is separated off, dried over MgSO 4 and filtered. After concentrating the ethereal solution, the solid, crude base is recrystallized from ethyl acetate. Mp. 100-105 0 C. After releasing the crystalline base in ethanol ethereal hydrochloric acid is added, the hydrochloride is isolated and recrystallized again from ethanol / ether. . Mp 187- 189 0 C, Yield: 1.9 g.
Berechnet: C 59,05, H 7,43, N 9,84;
gefunden: C 59,13, H 7,32, N 9,91.Calculated: C 59.05, H 7.43, N 9.84;
Found: C 59.13, H 7.32, N 9.91.
b) 2,38 g (0,01 Mol) l-(4-Aminophenoxy)-2-hydroxy-3-tert.-butylaminopropan (hergestellt durch Reduktion von 1-(4-Nitrophenoxy)-2-hydroxy-3-tert.-butylaminopropan mit katalytisch erregtem Wasserstoff) werden in einem Gemisch aus 5 ml konz. HCI und 20 ml H2O gelöst und dazu langsam bei 10"C unter Rührenb) 2.38 g (0.01 mol) of 1- (4-aminophenoxy) -2-hydroxy-3-tert-butylaminopropane (prepared by reducing 1- (4-nitrophenoxy) -2-hydroxy-3-tert .-Butylaminopropane with catalytically excited hydrogen) are concentrated in a mixture of 5 ml. HCl and 20 ml of H 2 O dissolved and added slowly at 10 ° C while stirring
40 1,4 g (0,02 Mol)NaNO2in 10 ml H2O zugetropft. Danach wird noch eine halbe Stunde bei 10°Cgerührt. 40 1.4 g (0.02 mol) of NaNO 2 in 10 ml of H 2 O were added dropwise. The mixture is then stirred for a further half an hour at 10 ° C.
Diese Lösung wird innerhalb 15 Minuten unter Rühren in ein Gemisch aus 5 g Kupfersulfat, 5,6 g Kaliumcyanid und 30 ml Wasser, das auf 90°C erhitzt ist. eingetropft. Danach wird noch 20 Minuten auf 80-90°C erhitzt.This solution is poured into a mixture of 5 g of copper sulphate, 5.6 g Potassium cyanide and 30 ml of water heated to 90 ° C. dripped in. The mixture is then heated to 80-90 ° C. for a further 20 minutes.
Nach Abkühlung wird mit HCl angesäuert und von unlöslichen verharzten Anteilen abgetrennt. Das wäßrige Filtrat wird mit NaOH alkalisch gestellt und zweimal mit CHCI3 extrahiert. Die Chloroformlösung wird mit Wasser gewaschen und über MgSO4 getrocknet. Der nach Abdestillieren des Chloroforms verbleibende Rückstand wird in wenig Äthanol gelöst, mit ätherischer HCl angesäuert und das ausfallende Hydrochlorid abgesaugt. Fp. 176-1790C.After cooling, it is acidified with HCl and separated from insoluble resinified components. The aqueous filtrate is made alkaline with NaOH and extracted twice with CHCl3. The chloroform solution is washed with water and dried over MgSO 4. The residue remaining after the chloroform has been distilled off is dissolved in a little ethanol, acidified with ethereal HCl and the precipitated hydrochloride is filtered off with suction. Mp. 176-179 0 C.
Berechnet: C 59,05, H 7,43, N 9,84;
gefunden: C 59,16, H 7,24, N 9,61.Calculated: C 59.05, H 7.43, N 9.84;
Found: C 59.16, H 7.24, N 9.61.
l-(3-Nitrilophenoxy)-2-hydroxy-3-tert.-butylaminopropan-Oxalat 1- (3-Nitrilophenoxy) -2-hydroxy-3-tert-butylaminopropane oxalate
9,6 g (0,05 Mol) 1-(3-Nitrilophenoxy)-3-aminopropanol-(2) werden in 40 ml Dimethylformamid gelöst, 100 ml Tetrahydrofuran zugegeben und 4,2 g (0,05 Mol) pulverisiertes Natriumbicarbonat eingetragen. Sodann werden 6,9 g (0,05 Mol) tert.-Butylbromid zugegeben und 24 Stunden unter Rückfluß erhitzt.9.6 g (0.05 mol) of 1- (3-nitrilophenoxy) -3-aminopropanol- (2) are dissolved in 40 ml of dimethylformamide, 100 ml of tetrahydrofuran added and 4.2 g (0.05 mol) powdered sodium bicarbonate entered. Then 6.9 g (0.05 mol) of tert-butyl bromide are added and refluxed for 24 hours.
Nach Abkühlung des Gemisches wird der anorganische Anteil abfiltriert, das Lösungsmittelgemisch i. Vak. abdestilliert und der Rückstand unter Erwärmen in Essigester gelöst. Die unlöslichen anorganischen Anteile werden angesaugt und das Filtrat mit Petroläther versetzt. Die Base fällt dabei in fester Form aus. Sie wird isoliert und aus Essigester unter Zugabe von Petroläther umkristallisiert. Fp. 108-1100C.After the mixture has cooled, the inorganic fraction is filtered off, the solvent mixture i. Vac. distilled off and the residue dissolved in ethyl acetate with heating. The insoluble inorganic components are sucked in and petroleum ether is added to the filtrate. The base precipitates out in solid form. It is isolated and recrystallized from ethyl acetate with the addition of petroleum ether. Mp. 108-110 0 C.
Berechnet: C 56,79, H 6,56, N 8,28;
gefunden: C 56,65, H 6,72, N 8,17.Calculated: C 56.79, H 6.56, N 8.28;
Found: C 56.65, H 6.72, N 8.17.
B e i s ρ i e 1 4B e i s ρ i e 1 4
( — )-l-(2-Nitrilophenoxy)-2-hydroxy-3-tert.-butyIaminopropan · HCI(-) -1- (2-Nitrilophenoxy) -2-hydroxy-3-tert-butylaminopropane · HCI
24,8 g (0,1 Mol) l-(2-NitriIophenoxy)-2-hydroxy-3-tert.-butylaminopropan (racemisch) werden in 100 ml abs. Methanol gelöst und mit einer Lösung von 38,6 g (0,1 Mol) ( —)-Di-p-toluylweinsäure in 150 ml abs. Methanol vereinigt. Nach mehrstündigem Stehen bei Raumtemperatur wird die Lösung filtriert und drei Tage bei 200C stehengelassen. Das langsam auskristallisierende Di-p-toluyltartrat wird sodann abgesaugt und nochmals in gleicher Weise umkristallisiert. Es werden 18,2 g( —)-1-(2-Nitrilophenoxy)-2-hydroxy-3-tert.-butylaminopropan-di-p-toluyltartrat vom Fp. 135— 137°C (Zers.) erhalten.24.8 g (0.1 mol) of 1- (2-nitriIophenoxy) -2-hydroxy-3-tert-butylaminopropane (racemic) are dissolved in 100 ml of abs. Dissolved methanol and with a solution of 38.6 g (0.1 mol) of (-) - di-p-toluyltartaric acid in 150 ml of abs. Methanol combined. After standing for several hours at room temperature, the solution is filtered and left to stand at 20 ° C. for three days. The di-p-toluyl tartrate, which slowly crystallizes out, is then filtered off with suction and recrystallized again in the same way. 18.2 g of (-) - 1- (2-nitrilophenoxy) -2-hydroxy-3-tert-butylaminopropane-di-p-toluyl tartrate with a melting point of 135-137 ° C. (decomposition) are obtained.
[<x]f= -90,5° C (in.Methanol).
6 g dieses Tartrates werden mit 100 ml Äther und 50 ml 1 N-NaOH geschüttelt. Die organische Phase
wird abgetrennt und über MgSO4 getrocknet. Nach Filtration wird ätherische HCI zugegeben, wobei
Kristallisation eintritt. Es werden 2,4 Hydrochlorid vom Fp. 161 —164° C gewonnen.
[λ]*?= +14,7° C (in Methanol). [<x] f = -90.5 ° C (in. methanol).
6 g of this tartrate are shaken with 100 ml of ether and 50 ml of 1N NaOH. The organic phase is separated off and dried over MgSO 4. After filtration, ethereal HCl is added, whereupon crystallization occurs. 2.4 hydrochloride with a melting point of 161-164 ° C. is obtained.
[λ] *? = + 14.7 ° C (in methanol).
Aus der Mutterlauge (methanolisch) des obengenannten Di-p-toluyltartrates kann nach Verdampfen des Methanols i. Vak. der rechtsdrehende Antipode erhalten und durch Behandlung mit NaOH die Base gewonnen werden. Sie läßt sich mit Hilfe von ätherischer HCI aus ätherischer Lösung als Hydrochlorid fällen.From the mother liquor (methanolic) of the above-mentioned di-p-toluyl tartrate can after evaporation of the Methanol i. Vac. the clockwise antipode is obtained and the base is obtained by treatment with NaOH will. It can be precipitated as hydrochloride from an ethereal solution with the help of ethereal HCI.
Claims (5)
h) eine Verbindung der Formel 10 in the R 4 and R 5 , which can be the same or different. Denotes hydrogen or an alkyl, aralkyl or aryl radical, hydrolyzed or pyrolyzed, or
h) a compound of the formula
f) ein Oxazolidinon der allgemeinen Formelhydrolytically cleaves,
f) an oxazolidinone of the general formula
J. Pharm. med. Chem. Bd. 5, S. 69 - 76 (1952),
|. Pharm. Pharmacol. Bd. With regard to the production of the starting material, reference is also made to the following literature:
J. Pharm. Med. Chem. Vol. 5, pp. 69-76 (1952),
|. Pharm. Pharmacol. Vol.
J. Pharm. Pharmacol. Bd.9, S. 10-19(1957),5, pp. 359-269 (1953).
J. Pharm. Pharmacol. Vol. 9, pp. 10-19 (1957),
BE-Patentschrift6 41 133,
Chemical Abstracts Bd. 58, 3337c (1962), sowieGB patent 8 94 189,
BE patent 6 41 133,
Chemical Abstracts Vol. 58, 3337c (1962), as well as
Priority Applications (59)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL136601D NL136601C (en) | 1967-06-15 | ||
DE1967B0093025 DE1593782B2 (en) | 1967-06-15 | 1967-06-15 | 1-NITRILOPHENOXY- 2- HYDROXY -3- TERT.BUTYLAMINOPROPANE, THE PROCESS FOR THEIR MANUFACTURING AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE |
FR1583559D FR1583559A (en) | 1967-06-15 | 1967-06-17 | |
US700376A US3541130A (en) | 1967-02-06 | 1968-01-25 | 1-(cyanophenoxy)-2-hydroxy-3-tert.-butylamine propanes |
JP43038048A JPS51100B1 (en) | 1967-06-15 | 1968-06-05 | |
ES354823A ES354823A1 (en) | 1967-06-15 | 1968-06-08 | Propanolamine derivatives |
NL6808196A NL6808196A (en) | 1967-06-15 | 1968-06-11 | |
YU135068A YU33262B (en) | 1967-06-15 | 1968-06-12 | Postopek za pripravo novih substiturnih 1-fenoksi -2-hidroksi-3-terc. butilamino-propanov |
SE07980/68A SE355571B (en) | 1967-06-15 | 1968-06-13 | |
CH1167670A CH509254A (en) | 1967-06-15 | 1968-06-13 | 1-Phenoxy-2-hydroxy-3-tert.-butylamino propanes - beta-adrenolytics, hypotensives |
CH876668A CH495950A (en) | 1967-06-15 | 1968-06-13 | 1-Phenoxy-2-hydroxy-3-tert.-butylamino propanes - beta-adrenolytics, hypotensives |
CH1167970A CH509257A (en) | 1967-06-15 | 1968-06-13 | 1-Phenoxy-2-hydroxy-3-tert.-butylamino propanes - beta-adrenolytics, hypotensives |
CH1168170A CH509973A (en) | 1967-06-15 | 1968-06-13 | 1-Phenoxy-2-hydroxy-3-tert.-butylamino propanes - beta-adrenolytics, hypotensives |
CH1167770A CH509255A (en) | 1967-06-15 | 1968-06-13 | 1-Phenoxy-2-hydroxy-3-tert.-butylamino propanes - beta-adrenolytics, hypotensives |
CH1167570A CH509253A (en) | 1967-06-15 | 1968-06-13 | 1-Phenoxy-2-hydroxy-3-tert.-butylamino propanes - beta-adrenolytics, hypotensives |
CH1167870A CH509256A (en) | 1967-06-15 | 1968-06-13 | 1-Phenoxy-2-hydroxy-3-tert.-butylamino propanes - beta-adrenolytics, hypotensives |
IE710/68A IE32373B1 (en) | 1967-06-15 | 1968-06-14 | Propanolamine derivatives |
AT248170A AT289080B (en) | 1967-06-15 | 1968-06-14 | Process for the preparation of new racemic or optically active 1-nitrilophenoxy- or 1-alkynyloxyphenoxy-2-hydroxy-3-tert-butylaminopropanes and their salts |
AT248070A AT289079B (en) | 1967-06-15 | 1968-06-14 | Process for the preparation of new racemic or optically active 1-nitrilophenoxy- or 1-alkynyloxyphenoxy-2-hydroxy-3-tert.-butylaminopropanes and their salts |
AT247870A AT289077B (en) | 1967-06-15 | 1968-06-14 | Process for the preparation of new racemic or optically active 1-nitrilophenoxy- or 1-alkynyloxyphenoxy-2-hydroxy-3-tert-butylaminopropanes and their salts |
AT572568A AT289067B (en) | 1967-06-15 | 1968-06-14 | Process for the preparation of new racemic or optically active 1-nitrilophenoxy- or 1-alkynyloxyphenoxy-2-hydroxy-3-tert-butylaminopropanes and their salts |
GB28529/68A GB1187546A (en) | 1967-06-15 | 1968-06-14 | Propanolamine derivatives |
BE716647D BE716647A (en) | 1967-06-15 | 1968-06-14 | |
DK281968AA DK127059B (en) | 1967-06-15 | 1968-06-14 | Analogous process for the preparation of substituted 1-phenoxy-2-hydroxy-3-tert-butylaminopropanes or their salts or the corresponding optically active antipodes. |
FI681664A FI48922C (en) | 1967-06-15 | 1968-06-14 | Process for the preparation of pharmaceutically active novel, both racemic and optically active substituted 1-phenoxy-2-hydroxy-3-tert-butyl aminopropanes and these salts. |
AT248370A AT289082B (en) | 1967-06-15 | 1968-06-14 | Process for the preparation of new racemic or optically active 1-nitrilophenoxy-2-hydroxy-3-tert.-butylaminopropanes and their salts |
AT247970A AT289078B (en) | 1967-06-15 | 1968-06-14 | Process for the preparation of new racemic or optically active 1-nitrilophenoxy- or 1-alkynyloxyphenoxy-2-hydroxy-3-tert-butylaminopropanes and their salts |
IL6830181A IL30181A (en) | 1967-06-15 | 1968-06-14 | 1-(substituted phenoxy)-2-hydroxy-3-tertiary butylaminopropanes,their preparation and pharmaceutical compositions containing them |
AT247770A AT289076B (en) | 1967-06-15 | 1968-06-14 | Process for the preparation of new racemic or optically active 1-nitrilophenoxy- or 1-alkynyloxyphenoxy-2-hydroxy-3-tert-butylaminopropanes and their salts |
AT248270A AT289081B (en) | 1967-06-15 | 1968-06-14 | Process for the preparation of new racemic or optically active 1-nitrilophenoxy- or 1-alkynyloxyphenoxy-2-hydroxy-3-tert-butylaminopropanes and their salts |
BG011630A BG15040A3 (en) | 1967-06-15 | 1968-06-15 | METHOD FOR OBTAINING NEW SUBSTITUTED 1-PHENOXY-2-HYDROXY-3-TERT.BUTYLAMINOPROPANE AND THEIR SALTS |
BG011632A BG15042A3 (en) | 1967-06-15 | 1968-06-15 | METHOD FOR OBTAINING NEW SUBSTITUTED 1-PHENOXY-2-HYDROXY-3-TERT. BUTYLAMINO PROPANE AND THEIR SALTS |
BG011628A BG15038A3 (en) | 1967-06-15 | 1968-06-15 | METHOD FOR OBTAINING NEW SUBSTITUTED 1-PHENOXY -2- HYDROXY -3- TERT.BUTYLAMINOPROPANE AND THEIR SALTS |
BG011627A BG15037A3 (en) | 1967-06-15 | 1968-06-15 | METHOD FOR OBTAINING NEW SUBSTITUTED 1-PHENOXY-2-HYDROXY- -3-TERT. BUTYLAMINOPROPANES AND THEIR SALTS |
BG011631A BG15041A3 (en) | 1967-06-15 | 1968-06-15 | METHOD FOR OBTAINING NEW SUBSTITUTED 1-PHENOXY 2-HYDROXY-3-TERT. BUTYLAMINO-PROPANES AND THEIR SALTS |
BG011629A BG15039A3 (en) | 1967-06-15 | 1968-06-15 | METHOD FOR OBTAINING NEW SUBSTITUTED 1-PHENOXY-2-HYDROXY- -3-TERT.BUTYLAMINOPROPANE AND THEIR SALTS |
FR166464A FR8162M (en) | 1967-06-15 | 1968-09-17 | |
ES368398A ES368398A1 (en) | 1967-06-15 | 1969-06-16 | Propanolamine derivatives |
ES69368396A ES368396A1 (en) | 1967-06-15 | 1969-06-16 | Propanolamine derivatives |
ES368401A ES368401A1 (en) | 1967-06-15 | 1969-06-16 | Propanolamine derivatives |
ES368395A ES368395A1 (en) | 1967-06-15 | 1969-06-16 | Propanolamine derivatives |
ES368399A ES368399A1 (en) | 1967-06-15 | 1969-06-16 | Propanolamine derivatives |
GB3825170A GB1318533A (en) | 1967-06-15 | 1970-08-07 | 3-2-cyanophenoxy-2-hydroxy-n-ethyl-propylamine |
NL7111854.A NL158171B (en) | 1967-06-15 | 1971-08-27 | METHOD FOR THE SELF-KNOWN PREPARATION OF A 1- (2-PROPARGYLOXYPHENOXY) 3-ALKYLAMINO 2-PROPANOL, METHOD FOR THE PREPARATION OF PREPARATIONS CONTAINING THIS COMPOUND AND THE PREPARATIONS CONTAINED. |
US408743A US3868460A (en) | 1967-02-06 | 1973-10-23 | Therapeutic compositions and method |
MY1973288A MY7300288A (en) | 1967-06-15 | 1973-12-31 | Propanolamine derivatives |
YU2290/74A YU33777B (en) | 1967-06-15 | 1974-08-21 | Process for preparing novel substituted 1-phenoxy-2-hydroxy-3-tert.-butylamino-propanes |
YU2289/74A YU33776B (en) | 1967-06-15 | 1974-08-21 | Process for preparing novel substituted 1-phenoxy-2-hydroxy-3-tert.-butylamino-propanes |
YU2291/74A YU33778B (en) | 1967-06-15 | 1974-08-21 | Process for preparing novel substituted 1-phenoxy-2-hydroxy-3-tert.-butylamino-propanes |
YU2288/74A YU33775B (en) | 1967-06-15 | 1974-08-21 | Process for preparing novel substituted 1-phenoxy-2-hydroxy-3-tert.-butylamino-propanes |
YU2293/74A YU35578B (en) | 1967-06-15 | 1974-08-21 | Process for preparing novel substituted 1-phenoxy-2-hydroxy-3-tert. butyl amino propanes |
YU2294/74A YU33780B (en) | 1967-06-15 | 1974-08-21 | Process for preparing novel substituted 1-phenoxy-2-hydroxy-3-tert.-butylamino-propanes |
YU2292/74A YU33779B (en) | 1967-06-15 | 1974-08-21 | Process for preparing novel substituted 1-phenoxy-2-hydroxy-3-tert.-butylamino-propanes |
US05/502,634 US3940489A (en) | 1967-02-06 | 1974-09-03 | Therapeutic compositions and method |
JP49119881A JPS5112613B1 (en) | 1967-06-15 | 1974-10-17 | |
US05/564,308 US3961071A (en) | 1967-02-06 | 1975-04-02 | Therapeutic compositions and method |
US05/571,790 US4039685A (en) | 1967-02-06 | 1975-04-25 | 1-phenoxy-2-hydroxy-3-tert.-butylamino propane antiarrhythmic compounds |
US05/656,000 US4036988A (en) | 1967-02-06 | 1976-02-06 | Therapeutic compositions and method |
IT7949447A IT7949447A0 (en) | 1967-02-06 | 1979-06-18 | 1-CYANOPHENOXY-2-HYDROXY-3-TERT.BUTYLAMINOPROPANES THEIR SALTS AND PREPARATION PROCEDURE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1967B0093025 DE1593782B2 (en) | 1967-06-15 | 1967-06-15 | 1-NITRILOPHENOXY- 2- HYDROXY -3- TERT.BUTYLAMINOPROPANE, THE PROCESS FOR THEIR MANUFACTURING AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE |
Publications (2)
Publication Number | Publication Date |
---|---|
DE1593782A1 DE1593782A1 (en) | 1972-04-20 |
DE1593782B2 true DE1593782B2 (en) | 1976-09-09 |
Family
ID=6986720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1967B0093025 Granted DE1593782B2 (en) | 1967-02-06 | 1967-06-15 | 1-NITRILOPHENOXY- 2- HYDROXY -3- TERT.BUTYLAMINOPROPANE, THE PROCESS FOR THEIR MANUFACTURING AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE |
Country Status (17)
Country | Link |
---|---|
JP (2) | JPS51100B1 (en) |
AT (8) | AT289077B (en) |
BE (1) | BE716647A (en) |
BG (6) | BG15041A3 (en) |
CH (1) | CH495950A (en) |
DE (1) | DE1593782B2 (en) |
DK (1) | DK127059B (en) |
ES (6) | ES354823A1 (en) |
FI (1) | FI48922C (en) |
FR (2) | FR1583559A (en) |
GB (1) | GB1187546A (en) |
IE (1) | IE32373B1 (en) |
IL (1) | IL30181A (en) |
MY (1) | MY7300288A (en) |
NL (2) | NL6808196A (en) |
SE (1) | SE355571B (en) |
YU (7) | YU33775B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3937834A (en) | 1970-10-02 | 1976-02-10 | Ciba-Geigy Corporation | Pharmaceutical preparations |
JPS57125772U (en) * | 1981-01-30 | 1982-08-05 | ||
DE3744371A1 (en) * | 1987-12-29 | 1989-07-13 | Jacobs Suchard Ag | PACKAGING FOR CONFECTIONERY |
DE4014252A1 (en) * | 1990-05-04 | 1991-11-07 | Boehringer Ingelheim Vetmed | (-)-1-(4'-Amino-3'-cyanophenyl)-2-iso-propyl-amino-ethanol - for treating fatty degeneration, obstructive lung disorders, allergic bronchial asthma, spastic bronchitis and premature labour |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL301580A (en) * | 1962-12-11 |
-
0
- NL NL136601D patent/NL136601C/xx active
-
1967
- 1967-06-15 DE DE1967B0093025 patent/DE1593782B2/en active Granted
- 1967-06-17 FR FR1583559D patent/FR1583559A/fr not_active Expired
-
1968
- 1968-06-05 JP JP43038048A patent/JPS51100B1/ja active Pending
- 1968-06-08 ES ES354823A patent/ES354823A1/en not_active Expired
- 1968-06-11 NL NL6808196A patent/NL6808196A/xx unknown
- 1968-06-13 CH CH876668A patent/CH495950A/en not_active IP Right Cessation
- 1968-06-13 SE SE07980/68A patent/SE355571B/xx unknown
- 1968-06-14 AT AT247870A patent/AT289077B/en active
- 1968-06-14 AT AT248070A patent/AT289079B/en active
- 1968-06-14 AT AT247970A patent/AT289078B/en not_active IP Right Cessation
- 1968-06-14 GB GB28529/68A patent/GB1187546A/en not_active Expired
- 1968-06-14 AT AT247770A patent/AT289076B/en not_active IP Right Cessation
- 1968-06-14 AT AT248270A patent/AT289081B/en active
- 1968-06-14 AT AT572568A patent/AT289067B/en not_active IP Right Cessation
- 1968-06-14 FI FI681664A patent/FI48922C/en active
- 1968-06-14 DK DK281968AA patent/DK127059B/en not_active IP Right Cessation
- 1968-06-14 AT AT248170A patent/AT289080B/en active
- 1968-06-14 IL IL6830181A patent/IL30181A/en unknown
- 1968-06-14 BE BE716647D patent/BE716647A/xx not_active IP Right Cessation
- 1968-06-14 AT AT248370A patent/AT289082B/en not_active IP Right Cessation
- 1968-06-14 IE IE710/68A patent/IE32373B1/en unknown
- 1968-06-15 BG BG011631A patent/BG15041A3/en unknown
- 1968-06-15 BG BG011632A patent/BG15042A3/en unknown
- 1968-06-15 BG BG011629A patent/BG15039A3/en unknown
- 1968-06-15 BG BG011627A patent/BG15037A3/en unknown
- 1968-06-15 BG BG011628A patent/BG15038A3/en unknown
- 1968-06-15 BG BG011630A patent/BG15040A3/en unknown
- 1968-09-17 FR FR166464A patent/FR8162M/fr not_active Expired
-
1969
- 1969-06-16 ES ES368401A patent/ES368401A1/en not_active Expired
- 1969-06-16 ES ES368399A patent/ES368399A1/en not_active Expired
- 1969-06-16 ES ES368398A patent/ES368398A1/en not_active Expired
- 1969-06-16 ES ES69368396A patent/ES368396A1/en not_active Expired
- 1969-06-16 ES ES368395A patent/ES368395A1/en not_active Expired
-
1973
- 1973-12-31 MY MY1973288A patent/MY7300288A/en unknown
-
1974
- 1974-08-21 YU YU2288/74A patent/YU33775B/en unknown
- 1974-08-21 YU YU2291/74A patent/YU33778B/en unknown
- 1974-08-21 YU YU2290/74A patent/YU33777B/en unknown
- 1974-08-21 YU YU2292/74A patent/YU33779B/en unknown
- 1974-08-21 YU YU2294/74A patent/YU33780B/en unknown
- 1974-08-21 YU YU2293/74A patent/YU35578B/en unknown
- 1974-08-21 YU YU2289/74A patent/YU33776B/en unknown
- 1974-10-17 JP JP49119881A patent/JPS5112613B1/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2615406A1 (en) | BETA ADRENERGIC RECEPTOR BLOCKER | |
EP0030380A1 (en) | 2,3-Indoledione derivatives, process for their preparation, intermediates, pharmaceutical compositions containing these 2,3-indoledione derivatives and their pharmaceutical use | |
DE1593782B2 (en) | 1-NITRILOPHENOXY- 2- HYDROXY -3- TERT.BUTYLAMINOPROPANE, THE PROCESS FOR THEIR MANUFACTURING AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE | |
EP0155518B1 (en) | S(-)-celiprolol, pharmaceutically acceptable salts, preparation and pharmaceutical compositions | |
DE1593782C3 (en) | 1-Nitrilophenoxy- 2- hydroxy -3-tertbutylaminopropane, process for their preparation and pharmaceutical preparations containing them | |
AT391866B (en) | METHOD FOR PRODUCING NEW S-TRIAZOLO (1,5-A) PYRIMIDINE | |
DE1593762A1 (en) | Process for the preparation of new substituted 1-phenoxy-2-hydroxy-3-alkylaminopropanes | |
DE2914166A1 (en) | ARYL-SUBSTITUTED FURANE AND METHOD FOR THEIR PRODUCTION | |
EP0037062B1 (en) | Substituted 3-aryl-2-cycloalkene-1-ones, process for their preparation and their parmaceutical use | |
DE1543391C3 (en) | 1- (2-Nitrilophenoxy) -2-hydroxy-3-isopropylaminopropane and its salts | |
DE2126169C3 (en) | Alkanolamine derivatives and pharmaceutical compositions containing them | |
DE1950351C3 (en) | 1- (2-Cyano-5-methylphenoxy) -2-hydroxy-3-aIkylaminopropane, process for their preparation and medicaments containing them | |
DE2617967C3 (en) | Process for the preparation of 2,4-diamino-5-benzylpyrimidines | |
DE959097C (en) | Process for the preparation of basic substituted diarylacetonitriles | |
AT346838B (en) | PROCESS FOR MANUFACTURING NEW OPTICALLY ACTIVE ANTHRACYCLINONES | |
AT289068B (en) | Process for the preparation of new racemic or optically active substituted 1-phenoxy-2-hydroxy-3-alkylaminopropanes and of their acid addition salts | |
DE1643237C3 (en) | Nuclear-substituted 1-nitrilophenoxy-3-tert-butylamino-2-propanols, processes for their production and pharmaceutical preparations based on them | |
AT282596B (en) | PROCESS FOR THE PRODUCTION OF NEW MIXED SUBSTITUTE 1-PHENOXY-3-ALKYLAMINOPROPANOL (2) AND THEIR ACID ADDITION SALTS | |
AT290503B (en) | Process for the preparation of new 1- (4'-acylaminophenoxy) -2-hydroxy-3-aminopropanes and their acid addition salts | |
AT258280B (en) | Process for the production of new benzofuran derivatives and their salts | |
AT297681B (en) | Process for the preparation of new äthinyl-substituted 1-phenoxy-2-hydroxy-3-butylaminopropanes, their optically active isomers and acid addition salts | |
DE1593901C3 (en) | Basically substituted benzofurans or indoles and processes for their preparation and pharmaceuticals containing these compounds | |
DE1668964A1 (en) | Novel trimethylhydroquinone derivatives and processes for making same | |
DE2135711A1 (en) | ||
DE1618160A1 (en) | AEthynyl-substituted 1-phenoxy-2-hydroxy-3-alkylaminopropanes and processes for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C3 | Grant after two publication steps (3rd publication) | ||
E77 | Valid patent as to the heymanns-index 1977 |